GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Shyndec Pharmaceutical Co Ltd (SHSE:600420) » Definitions » Equity-to-Asset

Shanghai Shyndec Pharmaceutical Co (SHSE:600420) Equity-to-Asset : 0.65 (As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Shanghai Shyndec Pharmaceutical Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Shanghai Shyndec Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Sep. 2024 was ¥13,075 Mil. Shanghai Shyndec Pharmaceutical Co's Total Assets for the quarter that ended in Sep. 2024 was ¥20,066 Mil. Therefore, Shanghai Shyndec Pharmaceutical Co's Equity to Asset Ratio for the quarter that ended in Sep. 2024 was 0.65.

The historical rank and industry rank for Shanghai Shyndec Pharmaceutical Co's Equity-to-Asset or its related term are showing as below:

SHSE:600420' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.28   Med: 0.42   Max: 0.65
Current: 0.65

During the past 13 years, the highest Equity to Asset Ratio of Shanghai Shyndec Pharmaceutical Co was 0.65. The lowest was 0.28. And the median was 0.42.

SHSE:600420's Equity-to-Asset is ranked better than
58.18% of 1033 companies
in the Drug Manufacturers industry
Industry Median: 0.6 vs SHSE:600420: 0.65

Shanghai Shyndec Pharmaceutical Co Equity-to-Asset Historical Data

The historical data trend for Shanghai Shyndec Pharmaceutical Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Shyndec Pharmaceutical Co Equity-to-Asset Chart

Shanghai Shyndec Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 0.44 0.45 0.53 0.64

Shanghai Shyndec Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.64 0.64 0.65 0.65

Competitive Comparison of Shanghai Shyndec Pharmaceutical Co's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Shyndec Pharmaceutical Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Shyndec Pharmaceutical Co's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Shyndec Pharmaceutical Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Shanghai Shyndec Pharmaceutical Co's Equity-to-Asset falls into.



Shanghai Shyndec Pharmaceutical Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Shanghai Shyndec Pharmaceutical Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=12388.361/19352.282
=0.64

Shanghai Shyndec Pharmaceutical Co's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )=Total Stockholders Equity/Total Assets
=13074.541/20066.164
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Shyndec Pharmaceutical Co  (SHSE:600420) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Shanghai Shyndec Pharmaceutical Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Shanghai Shyndec Pharmaceutical Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Shyndec Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No.1320 Beijinxi Road, Shanghai, CHN, 200040
Shanghai Shyndec Pharmaceutical Co Ltd engages in the research, development, production, and sale of pharmaceutical preparations, biological pharmaceuticals, chemical raw materials, and Chinese medicine formulations in China and internationally. It provides biological and chemical raw material medicines, microbial fermentation products and tablets, capsules, granules, injections, suspensions, and suppositories, as well as ointments, including product formulations.
Executives
Li Hao senior management
Ni Feng Director
Li Xian Lin senior management
Hao Chao Feng senior management
Lian Wan Yong Director
Han Yan Lin Director
Yang Wen Ming Supervisors
Feng Ming Director

Shanghai Shyndec Pharmaceutical Co Headlines

No Headlines